Free Trial

Advisors Preferred LLC Takes $368,000 Position in Grifols, S.A. (NASDAQ:GRFS)

Grifols logo with Medical background

Advisors Preferred LLC bought a new stake in shares of Grifols, S.A. (NASDAQ:GRFS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 52,943 shares of the biotechnology company's stock, valued at approximately $368,000.

Several other large investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Grifols by 5.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 33,200 shares of the biotechnology company's stock valued at $247,000 after acquiring an additional 1,657 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Grifols by 14.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 26,230 shares of the biotechnology company's stock valued at $186,000 after acquiring an additional 3,399 shares in the last quarter. Versant Capital Management Inc purchased a new position in shares of Grifols during the 1st quarter valued at $28,000. HighTower Advisors LLC grew its holdings in shares of Grifols by 28.3% during the 4th quarter. HighTower Advisors LLC now owns 17,866 shares of the biotechnology company's stock valued at $133,000 after acquiring an additional 3,936 shares in the last quarter. Finally, Cerity Partners LLC grew its holdings in shares of Grifols by 22.8% during the 1st quarter. Cerity Partners LLC now owns 22,254 shares of the biotechnology company's stock valued at $158,000 after acquiring an additional 4,129 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on GRFS shares. Wall Street Zen upgraded shares of Grifols from a "buy" rating to a "strong-buy" rating in a report on Monday, July 7th. JPMorgan Chase & Co. upped their price objective on shares of Grifols from $7.60 to $10.30 and gave the stock a "neutral" rating in a report on Tuesday, June 17th.

View Our Latest Stock Analysis on Grifols

Grifols Stock Performance

GRFS stock traded up $0.09 during mid-day trading on Thursday, reaching $9.94. 733,001 shares of the stock traded hands, compared to its average volume of 1,034,171. The company has a quick ratio of 0.97, a current ratio of 2.60 and a debt-to-equity ratio of 1.13. Grifols, S.A. has a 52 week low of $6.19 and a 52 week high of $10.30. The business has a 50-day moving average of $8.90 and a two-hundred day moving average of $7.90. The firm has a market capitalization of $6.83 billion, a PE ratio of 8.50, a P/E/G ratio of 0.37 and a beta of 0.55.

Grifols Company Profile

(Free Report)

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.

Further Reading

Institutional Ownership by Quarter for Grifols (NASDAQ:GRFS)

Should You Invest $1,000 in Grifols Right Now?

Before you consider Grifols, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.

While Grifols currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines